# negative symptoms in patients with schizophrenia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia

> No upcoming FDA catalysts in negative symptoms in patients with schizophrenia; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for negative symptoms in patients with schizophrenia?

No upcoming FDA catalysts in negative symptoms in patients with schizophrenia; 2 past events are recorded. SEC Form 10-Q: "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." [Calendar and source filings](https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia)

Source: SEC Form 10-Q, accession 0001193125-26-451797, https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-06. Cite: https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 27, 2023 | [Roluperidone NDA/BLA submission](https://sec-api.dev/pdufa/roluperidone) | NERV | negative symptoms in patients with schizophrenia | completed | "On April 27, 2023, the FDA filed our NDA for roluperidone following our request for formal dispute resolution and appeal of the refusal-to-file letter." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm)) |
| February 26, 2024 | [Roluperidone complete response letter (CRL)](https://sec-api.dev/pdufa/roluperidone) | NERV | negative symptoms in patients with schizophrenia | completed, complete response letter | "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm)) |

## Drugs

- [Roluperidone](https://sec-api.dev/pdufa/roluperidone) (NERV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "negative symptoms in patients with schizophrenia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia

```bibtex
@misc{secapidev_indications_negative_symptoms_in_patients_with_schizophrenia_20261116,
  title        = {negative symptoms in patients with schizophrenia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_negative_symptoms_in_patients_with_schizophrenia_20261116","title":"negative symptoms in patients with schizophrenia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
